APA (7th ed.) Citation

DJ, G., C, H., S, H., MD, M., O, H., M, W., . . . TK, C. (2019). Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. The oncologist, 24(11), 1497. https://doi.org/10.1634/theoncologist.2019-0316

Chicago Style (17th ed.) Citation

DJ, George, et al. "Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN Trial." The Oncologist 24, no. 11 (2019): 1497. https://doi.org/10.1634/theoncologist.2019-0316.

MLA (9th ed.) Citation

DJ, George, et al. "Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN Trial." The Oncologist, vol. 24, no. 11, 2019, p. 1497, https://doi.org/10.1634/theoncologist.2019-0316.